|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Multivariable analysis identified diabetes (BRI of patients with diabetes vs. patients without diabetes: 0.34 ± 0.13 vs. 0.58 ± 0.22; p = .002) and presence of Peri-strut low intensity areas (PSLIA, BRI of 10 patients with PSLIA vs. 26 patients without PSLIA: 0.44 ± 0.21 vs. 0.61 ± 18; p = .027) as independent predictors for a prolonged BRS resorption, whereas the resorption rate in ACS patients (STEMI, NSTEMI, and unstable angina; n = 13) was significantly higher as compared to patients without ACS (0.62 ± 0.17 vs. 0.43 ± 0.24; p = .012).
|
30945432 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
No interaction was observed according to patients' risk profile or the rate of diabetes and ACS.
|
31730255 |
2019 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Hierarchical classification analysis showed that for north Greek areas family history of coronary heart disease, hypercholesterolemia, hypertension, diabetes (explained variability 35%), and less significantly, dietary habits, smoking, body mass index, and physical activity status (explained variability 4%) were associated with the development of ACS, whereas for south Greek areas hypercholesterolemia, family history of coronary heart disease, diabetes, smoking, hypertension, dietary habits, physical activity (explained variability 34%), and less significantly body mass index (explained variability <1%), were associated with the development of the disease.
|
18388034 |
2008 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
40 ACS patients with prior history of CHD and diabetes while the onset time of diabetes preceded that of CHD by more than 2 years were enrolled as the DACS group(diabetic ACS group).
|
30670045 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Diabetes is not associated with increased rates of free flap failure: Analysis of outcomes in 6030 patients from the ACS-NSQIP database.
|
29719063 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Mean age was 66±12years with diabetes in 20.7%, previous infarction in 22.7%, and ACS as the indication in 71.2% of patients.
|
28385356 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Independent predictors for TLF were ACS and diabetes mellitus (HR 4.67; 95% CI: 1.78-12.3; P = 0.002 and HR 3.37; 95% CI: 1.38-8.26; P = 0.008, respectively).
|
27414021 |
2017 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
There were 20.8% of patients with NSTE-ACS, 93.8% with hypertension, 35.4% with diabetes, 52.1% had previous MI, and 47.9% and 14.6% underwent prior PCI and coronary artery bypass grafting, respectively.The device success rate was 100%.
|
29192951 |
2018 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
This study aimed to examine the impact of diabetes on postoperative outcomes following surgical management of pressure ulcers using the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database.
|
30663823 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Statin use was highest for recent ACS and lowest for DM alone.
|
29499359 |
2018 |
|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
ACS-AZ10 (15 or 30mg/kg) displayed significant antitumor activity considering the tumor weight and volume, cell viability, and total Ehrlich cell count.
|
28364597 |
2017 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
The American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database was queried for patients undergoing craniotomy for tumor from 2006 to 2015.
|
29625308 |
2018 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
The low, medium and high dose of ACS c-SLN combinations exhibited a reduction in tumor incidence (PanIN count) by 16.6% (P < 0.01), 66.8% (P < 0.01), and 83.4% (P < 0.01), respectively.
|
30416852 |
2018 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Recently, membrane-coated nanomaterials mimicking source cells of interest have emerged as powerful tools that can be used for improved tumor targeting and as "nanotraps" to capture chemokines and bacterial toxins.In this issue of ACS Nano, Lapek et al. demonstrate that membrane-coated nanosponges in combination with quantitative proteomics can also be used as efficient "fishing devices" for the identification of cell-type-specific virulence factors.
|
29154537 |
2017 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Higher expression levels were observed in normal lung tissue than in the tumor counterpart, with median relative quantification ratios between normal and tumor varying from 1.90 to 7.78; the difference was statistically significant (P < 0.001, Wilcoxon's signed-rank test for paired samples) for eight transcripts: ELAVL1-TIMM44, FAM162B-ZUFSP, IFNAR2-IL10RB, INMT-FAM188B, KIAA1841-C2orf74, NFATC3-PLA2G15, SIRPB1-SIRPD, and SHANK3-ACR.
|
27058892 |
2016 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
The American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database was queried to determine 30-day outcomes following surgery for IDEM tumors between 2005 and 2016.
|
29902605 |
2018 |
|
Cerebrovascular accident
|
0.060 |
Biomarker
|
group |
BEFREE |
ABBREVIATIONS ACA = anterior cerebral artery; AChA = anterior choroidal artery; ACS NSQIP-P = American College of Surgeons National Surgical Quality Improvement Program–Pediatric; CVA = cerebrovascular accident; DWI = diffusion weighted imaging; iMRI = intraoperative MRI; MCA = middle cerebral artery; mRS = modified Rankin Scale; PCA = posterior cerebral artery.
|
30579265 |
2018 |
|
Cerebrovascular accident
|
0.060 |
Biomarker
|
group |
BEFREE |
Risk factors involved in atherosclerotic stroke and anterior and posterior circulation strokes (ACS and PCS, respectively) are different.
|
27796172 |
2017 |
|
Cerebrovascular accident
|
0.060 |
Biomarker
|
group |
BEFREE |
The current study examines how stroke severity (NIH Stroke Scale), its impact on perceived mobility (Stroke Impact Scale mobility domain), and the environment (MOS Social Support-Positive Social Interactions scale and Measure of Stroke Environment receptivity and built environment domains) influence social participation (Activity Card Sort: ACS).
|
30800187 |
2019 |
|
Cerebrovascular accident
|
0.060 |
Biomarker
|
group |
BEFREE |
Circulating DNA and RNA concentrations are elevated early in patients with trauma, stroke and ACS, and are generally highest in patients with a high risk of death.
|
17108220 |
2006 |
|
Cerebrovascular accident
|
0.060 |
Biomarker
|
group |
BEFREE |
Each offers a relative efficacy benefit (dual antiplatelet therapy [DAPT] is more effective than OAC alone in reducing cardiovascular death, myocardial infarction, stent thrombosis, and ischemic coronary events in a population with acute coronary syndromes [ACS]), but with a relative compromise (DAPT is significantly inferior to OAC for the prevention of stroke/systemic embolism in an AF population at increased risk of stroke).
|
30404748 |
2018 |
|
Cerebrovascular accident
|
0.060 |
Biomarker
|
group |
BEFREE |
Primary outcome was newly-developed MACE composed of cardiovascular death, ACS, coronary revascularization, or non-hemorrhagic stroke.
|
30093717 |
2018 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Medication-specific coronary effects (vasospasm, endothelial dysfunction, spontaneous thrombosis, accelerated atherosclerosis), radiation vasculitis, cancer cell coronary embolism, and coronary compression from thoracic malignancies are unique ACS mechanisms in cancer patients.
|
30132257 |
2018 |
|
Malignant Neoplasms
|
0.050 |
GeneticVariation
|
group |
BEFREE |
Using ACS NSQIP data (2014-2017), patients who underwent preoperative biliary drainage prior to hepatobiliary resection for malignancy were identified.
|
31350104 |
2020 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
The ACS/ASCO 2016 Breast Cancer Survivorship Care Guideline (Guideline) reflects comprehensive literature review through April 2015, while the jointly sponsored, inaugural Cancer Survivorship Symposium in 2016 (Symposium) reflects ongoing research activity in the area.
|
29332134 |
2018 |